The most crucial path passes through the phenotype Ph+ ALL, the disease chronic myelogenous leukemia, BCR-ABL1 positive, and the gene BCR, before connecting to Bosutinib via the drug protein relation (Figure 3D, right). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.